ACTIV-2: A Study for Outpatients With COVID-19, National Institute of Allergy and Infectious Diseases (NIAID)

Objective

Goal: To study the safety and effectiveness of different drugs in treating COVID-19 in outpatients.

• Phase III, randomized, blinded, placebo-controlled trial.
• Subjects in the study will be treated with either a study drug or with placebo.
• Multicenter trial with 2000 subject enrollment goal.

Investigator

Dr. Francis Riedo, EvergreenHealth Infectious Disease Care

Clinical Trial Categories

• COVID-19